Literature DB >> 16293102

Medical devices for the diagnosis and treatment of obstructive sleep apnea.

Peter A Cistulli1, Ronald R Grunstein.   

Abstract

Obstructive sleep apnea is increasingly being recognized as a serious public health problem, and is characterized by repetitive, complete or partial closure of the upper airway during sleep, resulting in sleep fragmentation and oxygen desaturation. The key symptoms of obstructive sleep apnea are snoring, witnessed apneas, excessive daytime sleepiness and deficits in neurocognitive function, adversely impacting on quality of life. The last 10 years have seen a steady increase in evidence linking obstructive sleep apnea to long-term cardiovascular morbidity, including hypertension, myocardial infarction and stroke, and an increased risk of motor vehicle accidents. The discovery of continuous positive airway pressure treatment, and the resultant recognition of the high prevalence of snoring and obstructive sleep apnea, and their impact on health, has spawned a new and rapidly growing global industry. Whilst diagnostic technologic advancements have evolved relatively rapidly, many questions relating to the use of such devices in clinical practice remain unresolved. Similarly, on the therapeutic front, advances in continuous positive airway pressure technology have broadened the use of such treatment, although compliance remains an important impediment to widespread treatment of this common disorder. This has prompted a search for simpler treatment alternatives, ranging from surgical, medical and dental therapies, although none have matched the efficacy of continuous positive airway pressure. Advances in our understanding of the neurobiology of sleep and respiration herald the prospect of pharmacologic treatment in the longer term.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16293102     DOI: 10.1586/17434440.2.6.749

Source DB:  PubMed          Journal:  Expert Rev Med Devices        ISSN: 1743-4440            Impact factor:   3.166


  7 in total

1.  Snoring as a risk factor for sexual dysfunction in community men.

Authors:  Viktor Hanak; Debra J Jacobson; Michaela E McGree; Jennifer St Sauver; Michael M Lieber; Eric J Olson; Virend K Somers; Naomi M Gades; Steven J Jacobsen
Journal:  J Sex Med       Date:  2007-12-17       Impact factor: 3.802

2.  Changes in regional adiposity and cardio-metabolic function following a weight loss program with sibutramine in obese men with obstructive sleep apnea.

Authors:  Craig L Phillips; Brendon J Yee; Mike I Trenell; John S Magnussen; David Wang; Dev Banerjee; Norbert Berend; Ronald R Grunstein
Journal:  J Clin Sleep Med       Date:  2009-10-15       Impact factor: 4.062

3.  Two randomized placebo-controlled trials to evaluate the efficacy and tolerability of mirtazapine for the treatment of obstructive sleep apnea.

Authors:  Nathaniel S Marshall; Brendon J Yee; Anup V Desai; Peter R Buchanan; Keith K H Wong; Renee Crompton; Kerri L Melehan; Nadene Zack; Srinivas G Rao; R Michael Gendreau; Jay Kranzler; Ronald R Grunstein
Journal:  Sleep       Date:  2008-06       Impact factor: 5.849

Review 4.  Adult obstructive sleep apnoea.

Authors:  Amy S Jordan; David G McSharry; Atul Malhotra
Journal:  Lancet       Date:  2013-08-02       Impact factor: 79.321

5.  Reliability of Sonoelastography Measurement of Tongue Muscles and Its Application on Obstructive Sleep Apnea.

Authors:  Cheng-An Chu; Yunn-Jy Chen; Ke-Vin Chang; Wei-Ting Wu; Levent Özçakar
Journal:  Front Physiol       Date:  2021-03-25       Impact factor: 4.566

6.  Excessive Daytime Sleepiness in Obstructive Sleep Apnea. Mechanisms and Clinical Management.

Authors:  Chitra Lal; Terri E Weaver; Charles J Bae; Kingman P Strohl
Journal:  Ann Am Thorac Soc       Date:  2021-05

7.  Effects of solriamfetol in a long-term trial of participants with obstructive sleep apnea who are adherent or nonadherent to airway therapy.

Authors:  Paula K Schweitzer; Kingman P Strohl; Geert Mayer; Russell Rosenberg; Patricia Chandler; Michelle Baladi; Lawrence Lee; Atul Malhotra
Journal:  J Clin Sleep Med       Date:  2021-04-01       Impact factor: 4.062

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.